![Jimmy Vanhove](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jimmy Vanhove
Algemeen Directeur bij Viralgen Vector Core SL
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Javier García Cogorro | M | - |
Viralgen Vector Core SL
![]() Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | - |
Richard Samulski | M | - |
Viralgen Vector Core SL
![]() Viralgen Vector Core SL BiotechnologyHealth Technology Viralgen Vector Core SL is a contract development and manufacturing organization (CDMO) that produces AAV gene therapy treatments for pharmaceutical and biotech companies. The company was founded in 2017 by Javier García Cogorro and is based in Donostia-San Sebastian, Spain. Viralgen offers the Pro10™ based suspension manufacturing platform, which increases scalability, performance, and yield of AAV therapies. The Spanish company's clinical facilities have four CGMP manufacturing suites, with 250-liter and 500-liter bioreactors. In 2020, Viralgen expanded within the scientific park by constructing a new building for large-scale commercial manufacturing. The new state-of-the-art space includes three additional CGMP suites with a manufacturing capacity of >2,000 liters each, as well as a suite dedicated to fully automated fill and finish operations. The new facility has received the CGMP certification by the Spanish Agency for Medicines and Medical Devices (AEMPS) as part of the EMA network. The CEO is Jimmy Vanhove. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Spanje | 2 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jimmy Vanhove
- Persoonlijk netwerk